Dermatology Grand Rounds
Dermatology Lecture Hall
The Donald L. Levin, MD Lectureship
This annual lectureship has been made possible by the generosity of Dr. Donald L. Levin.
Grand Rounds
Wednesday, May 15, 2019, 08:00 AM
676 North Saint Clair Street, Suite 1600 (16th Floor)
Mechanisms of Pathogenesis of Chronic Sinus Disease
Robert P. Schleimer, PhD
Chief of Allergy and Immunology in the Department of Medicine
Roy and Elaine Patterson Professor of Medicine
Professor of Medicine (Allergy and Immunology), Microbiology-Immunology and Otolaryngology - Head and Neck Surgery
Northwestern University Feinberg School of Medicine
Dr. Schleimer majored in Biology at The University of California, San Diego. He received a Ph.D. in Pharmacology and Toxicology at UC Davis. Dr. Schleimer received post-doctoral fellowship training at the Johns Hopkins University School of Medicine in the Division of Clinical Immunology. Dr. Schleimer joined the faculty at Johns Hopkins in 1981 and became Professor of Medicine in 1992. Dr. Schleimer moved to Chicago to become the Roy and Elaine Patterson Chair and Chief of the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine in the spring of 2004. Dr. Schleimer has published over 380 papers and was recognized as one of the most highly cited researchers of the last two decades worldwide by The Institute for Scientific Information (ISI).
He has had continuous NIH funding for 35 years and presently has a MERIT award to study glucocorticoids, a T32 training grant and an R01 on AERD as PI. He has served on numerous NIH committees and advisory boards for pharmaceutical companies and biotechnology firms. Dr. Schleimer is a cofounder of Allakos, a company developing a new therapy for a variety of allergic diseases mediated by mast cells and eosinophils. He is presently actively involved in studying the molecular mechanisms of allergic disease, focusing on inflammation, innate and adaptive immunity, cytokines and chemokines, food allergy, the molecular basis for anti-inflammatory steroid action in allergic diseases and the mechanisms of pathogenesis in Chronic Rhinosinusitis.
Atopic Dermatitis: Unleashing the Power of Translational Medicine
Lisa A. Beck, MD
Deans Professor of Dermatology, Medicine and Pathology
University of Rochester Medical Center
Rochester, NY
Dr. Beck is a Tenured Professor of Dermatology, with secondary appointments in Allergy, Immunology and Rheumatology (Medicine) and Pathology. She has had a longstanding interest in characterizing cutaneous allergic inflammation with a specific focus on Atopic Dermatitis (or eczema). Her laboratory was the first to demonstrate that the activation status of white blood cells or leukocytes affected their in vivo responsiveness to naturally occurring chemotactic proteins called chemokines. Her laboratory observed that these chemokines also act on structural cells, and that they may function as mediators of fibrosis and/or epithelial barrier repair. More recently, her laboratory has been exploring the dynamic interaction between the skin barrier and the innate and adaptive immune systems. She was the first to describe and characterize epidermal tight junction (TJ) defects in atopic dermatitis.
Dr. Beck is internationally recognized as an eczema expert, her research was instrumental in the development of the first biologic drug called dupilumab (or Dupixent) for the treatment of adults with moderate to severe eczema. She was the lead author of a 2014 New England Journal of Medicine paper that set the stage for the FDA approval of this drug in March 2017. She has had continuous NIH funding to study allergic inflammation and epithelial barrier function since 1994. She is currently involved in an NIH-funded study to determine why atopic dermatitis patients are susceptible to widespread skin infections with herpes simplex virus or Staphylococcus aureus. Dr. Beck has been Associate and Section Editor for JID, member of the ABD, member of the NEA Scientific Advisory Board, Board member and Vice President of the SID, secretary of the International Eczema Council and both standing and ad hoc reviewer for NIH study sections. She has published over 100 papers and numerous review articles.
Schedule of Events:
8:00 am - 9:00 am
Research Presentation
9:00 am–9:30 am
Patient Viewing
9:30 am–10:30 am
Case Discussion
10:45 am-12:00 pm
Main Presentation
Overall meeting objectives:
Course Objectives:
At the conclusion of this activity, participants should be able to:
1. Discuss new technology used in addressing dermatologic problems.
2. Understand the choices and risks for treating skin disease.
3. Discuss the ethical issues that arise in patient care.
4. Recognize the relevance of new laboratory discoveries to clinical issues.
Accreditation Statement:
The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement:
Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Course Director Disclosure: Amy S. Paller, MD, MS has disclosed the following relevant financial relationships:
Serves as a consultant (with honoraria) for the following companies: AbbVie, Anacor Pharmaceuticals, Inc., Celgene Corporation, Chugai Pharma, Galderma Laboratories, L.P. LEO Pharma US, Novartis Pharmaceuticals Corp., Onset Dermatologics, Promius Pharma, LLC. Scioderm, Shire, and Stiefel a GSK company.
Serves as a Principal Investigator (no honoraria) for the following companies: Amgen, Anacor Pharmaceuticals, Inc., Scioderm, and TopMD.
FSM’s CME leadership and staff have nothing to disclose:
Clara J. Schroedl, MD, Medical Director of CME, Sheryl Corey, Manager of CME, Jen Banys, Senior Program Administrator, Allison McCollum, Senior Program Coordinator, and Rhea Alexis Banks, Administrative Assistant 2.
http://www.feinberg.northwestern.edu/sites/dermatology/index.html
Disclosure(s):
Robert P. Schleimer, PhD discloses the following:
Research grant
National Institutes of Health
Serves as a consultant with the following
ActoBio Therapeutics
Lyra Therapeutics
Allakos
Sanofi-Aventis
Genentech, Inc.
Serves as a consultant with stock options (not yet valued)
Aqualung Therapeutics Corp
BioMarck
Exicure Inc
Lisa A Beck, MD discloses the following information:
Has contracted research with the following
Abbvie
Pfizer, Inc.
Leo Pharma
Regeneron
Serves as a consultant with the following
Abbvie
AstraZeneca
Lilly
Novartis AG
Regeneron
Leo Pharma
Sanofi-Aventis
Upcoming Dermatology Events
Dermatology Grand Rounds
Wednesday, Jun 19, 2019, 08:00 AM
676 N St Clair St, Chicago, IL, United States
Kathleen J. Green, PhD
Joseph L. Mayberry, Sr. Professor of Pathology
Professor of Dermatology
Associate Director of Basic Sciences, Robert H. Lurie Comprehensive Cancer Center
Michael D. Rosenblum, MD, PhD
Assistant Professor
Department of Dermatology
University of California San Francisco
San Francisco, CA